Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 30 | 2021 | 8860 | 1.390 |
Why?
|
| Radiosurgery | 13 | 2020 | 1328 | 1.000 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 401 | 0.950 |
Why?
|
| Spinal Neoplasms | 9 | 2020 | 760 | 0.830 |
Why?
|
| Radiotherapy | 4 | 2013 | 1525 | 0.680 |
Why?
|
| Meningioma | 7 | 2020 | 1209 | 0.600 |
Why?
|
| Glioma | 8 | 2019 | 3401 | 0.510 |
Why?
|
| Meningeal Neoplasms | 5 | 2021 | 1241 | 0.460 |
Why?
|
| Infratentorial Neoplasms | 1 | 2013 | 94 | 0.440 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 160 | 0.420 |
Why?
|
| SEER Program | 2 | 2013 | 1508 | 0.400 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2021 | 65 | 0.370 |
Why?
|
| Ependymoma | 1 | 2013 | 334 | 0.370 |
Why?
|
| Combined Modality Therapy | 14 | 2022 | 8628 | 0.360 |
Why?
|
| Radiation Injuries | 5 | 2020 | 1178 | 0.360 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2020 | 1770 | 0.320 |
Why?
|
| Neurofibromatosis 1 | 1 | 2011 | 568 | 0.270 |
Why?
|
| Postoperative Period | 4 | 2020 | 1841 | 0.270 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 13096 | 0.270 |
Why?
|
| Radiotherapy Dosage | 9 | 2019 | 2878 | 0.260 |
Why?
|
| Cerebellar Neoplasms | 2 | 2022 | 587 | 0.260 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2018 | 5221 | 0.260 |
Why?
|
| Medulloblastoma | 2 | 2022 | 683 | 0.260 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 895 | 0.260 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 640 | 0.250 |
Why?
|
| Melanoma | 6 | 2019 | 5475 | 0.250 |
Why?
|
| Survival Analysis | 7 | 2021 | 10250 | 0.240 |
Why?
|
| Deoxycytidine | 1 | 2008 | 825 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2008 | 546 | 0.240 |
Why?
|
| Salvage Therapy | 4 | 2018 | 1275 | 0.220 |
Why?
|
| Spine | 4 | 2020 | 1145 | 0.220 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 20817 | 0.210 |
Why?
|
| Glioblastoma | 2 | 2018 | 3481 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2006 | 1101 | 0.210 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 6352 | 0.210 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 802 | 0.200 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 6773 | 0.190 |
Why?
|
| Cicatrix | 1 | 2006 | 764 | 0.190 |
Why?
|
| Immunotherapy | 5 | 2020 | 4440 | 0.180 |
Why?
|
| Middle Aged | 40 | 2022 | 213367 | 0.180 |
Why?
|
| Prognosis | 12 | 2019 | 29050 | 0.160 |
Why?
|
| Male | 44 | 2021 | 350027 | 0.160 |
Why?
|
| Neurosecretory Systems | 1 | 2019 | 231 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 1660 | 0.150 |
Why?
|
| Aged | 29 | 2021 | 163253 | 0.150 |
Why?
|
| Breast | 1 | 2006 | 1969 | 0.150 |
Why?
|
| Electrons | 1 | 2018 | 269 | 0.150 |
Why?
|
| Hypopituitarism | 1 | 2019 | 254 | 0.140 |
Why?
|
| Female | 43 | 2021 | 380197 | 0.140 |
Why?
|
| Survival Rate | 7 | 2019 | 12781 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6535 | 0.140 |
Why?
|
| Organs at Risk | 1 | 2018 | 346 | 0.140 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 57768 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2020 | 491 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 2237 | 0.130 |
Why?
|
| Humans | 61 | 2022 | 744220 | 0.130 |
Why?
|
| Methionine | 1 | 2018 | 590 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 783 | 0.130 |
Why?
|
| Adult | 29 | 2022 | 214035 | 0.120 |
Why?
|
| Disease-Free Survival | 5 | 2022 | 6893 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 627 | 0.120 |
Why?
|
| Photons | 1 | 2018 | 588 | 0.120 |
Why?
|
| Retrospective Studies | 21 | 2022 | 77426 | 0.120 |
Why?
|
| Fractures, Compression | 1 | 2016 | 133 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 5529 | 0.120 |
Why?
|
| World Health Organization | 3 | 2015 | 1318 | 0.120 |
Why?
|
| Carbazoles | 1 | 2015 | 226 | 0.120 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2014 | 54 | 0.120 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 39045 | 0.120 |
Why?
|
| Ilium | 1 | 2014 | 154 | 0.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 1624 | 0.110 |
Why?
|
| Treatment Outcome | 17 | 2020 | 63119 | 0.110 |
Why?
|
| Credentialing | 1 | 2013 | 126 | 0.110 |
Why?
|
| Disease Progression | 9 | 2019 | 13280 | 0.100 |
Why?
|
| Brachytherapy | 1 | 2019 | 1246 | 0.100 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2011 | 22 | 0.100 |
Why?
|
| Young Adult | 12 | 2022 | 56436 | 0.100 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2011 | 44 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 9230 | 0.100 |
Why?
|
| Receptor, erbB-2 | 2 | 2018 | 2416 | 0.090 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2011 | 140 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 989 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 1284 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11493 | 0.090 |
Why?
|
| Neurosurgical Procedures | 5 | 2020 | 2003 | 0.090 |
Why?
|
| Spinal Fractures | 1 | 2016 | 696 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2011 | 281 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 1623 | 0.080 |
Why?
|
| ras Proteins | 1 | 2014 | 1060 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2019 | 2619 | 0.080 |
Why?
|
| Nausea | 2 | 2021 | 668 | 0.080 |
Why?
|
| Adolescent | 10 | 2022 | 85759 | 0.080 |
Why?
|
| Hippocampus | 1 | 2020 | 3676 | 0.080 |
Why?
|
| Piperidines | 1 | 2015 | 1605 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 5670 | 0.070 |
Why?
|
| Brain | 5 | 2019 | 26413 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 4553 | 0.070 |
Why?
|
| Rosaniline Dyes | 1 | 2005 | 51 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 11074 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 3130 | 0.070 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 1346 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6274 | 0.060 |
Why?
|
| Necrosis | 2 | 2019 | 1643 | 0.060 |
Why?
|
| Income | 1 | 2013 | 1913 | 0.060 |
Why?
|
| Carcinoma, Lobular | 2 | 2005 | 484 | 0.060 |
Why?
|
| Ki-67 Antigen | 2 | 2017 | 644 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 4245 | 0.060 |
Why?
|
| Nomograms | 1 | 2005 | 228 | 0.060 |
Why?
|
| Breast Neoplasms, Male | 1 | 2005 | 210 | 0.060 |
Why?
|
| Cystectomy | 1 | 2008 | 686 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 2041 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4837 | 0.060 |
Why?
|
| Adenoma | 1 | 2014 | 2174 | 0.060 |
Why?
|
| Disease Management | 1 | 2014 | 2458 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 13409 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2525 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2018 | 40992 | 0.050 |
Why?
|
| Algorithms | 2 | 2019 | 13885 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 4841 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2016 | 4041 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 12355 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 2030 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2006 | 956 | 0.050 |
Why?
|
| Anorexia | 1 | 2021 | 159 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 708 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 4929 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7281 | 0.050 |
Why?
|
| Cesium Radioisotopes | 1 | 2019 | 36 | 0.050 |
Why?
|
| Procarbazine | 1 | 2019 | 181 | 0.040 |
Why?
|
| Lomustine | 1 | 2019 | 59 | 0.040 |
Why?
|
| Hepatitis | 1 | 2021 | 227 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2008 | 1887 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 2019 | 377 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7784 | 0.040 |
Why?
|
| Neoplasms | 2 | 2021 | 21672 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 18367 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 1692 | 0.040 |
Why?
|
| Child | 4 | 2019 | 77679 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2019 | 367 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2019 | 284 | 0.040 |
Why?
|
| Radiography | 3 | 2014 | 7022 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 1036 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2020 | 497 | 0.040 |
Why?
|
| Cognition | 1 | 2015 | 6765 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2017 | 172 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2019 | 658 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2005 | 3469 | 0.040 |
Why?
|
| Vomiting | 1 | 2020 | 635 | 0.040 |
Why?
|
| Exanthema | 1 | 2021 | 501 | 0.040 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2019 | 286 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15070 | 0.040 |
Why?
|
| Risk Factors | 4 | 2019 | 72280 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2019 | 1032 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2019 | 665 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2727 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 1401 | 0.030 |
Why?
|
| Time Factors | 4 | 2019 | 40063 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 578 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2014 | 157 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 40559 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 876 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1531 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2018 | 1062 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 871 | 0.030 |
Why?
|
| Fever | 1 | 2021 | 1614 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2505 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2019 | 555 | 0.030 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 284 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 972 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1061 | 0.030 |
Why?
|
| Colitis | 1 | 2021 | 1170 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 12244 | 0.030 |
Why?
|
| Neurosurgery | 1 | 2019 | 643 | 0.030 |
Why?
|
| Groin | 1 | 2013 | 103 | 0.030 |
Why?
|
| Axilla | 2 | 2005 | 595 | 0.030 |
Why?
|
| Fractures, Spontaneous | 1 | 2014 | 230 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2914 | 0.030 |
Why?
|
| Biopsy | 2 | 2014 | 6757 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 324 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2020 | 1372 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3474 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1003 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 1914 | 0.020 |
Why?
|
| Quality of Life | 3 | 2019 | 12805 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1849 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 610 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 2455 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 11007 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3614 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 35129 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2019 | 53280 | 0.020 |
Why?
|
| Mutation | 3 | 2019 | 29784 | 0.020 |
Why?
|
| Consensus | 1 | 2017 | 2958 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2726 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1097 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13668 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10949 | 0.020 |
Why?
|
| Visual Perception | 1 | 2016 | 1420 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2011 | 749 | 0.020 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 388 | 0.020 |
Why?
|
| Learning | 1 | 2016 | 1713 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 1525 | 0.020 |
Why?
|
| Incidence | 2 | 2016 | 20945 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 931 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 2389 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 2732 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 8343 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2011 | 975 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 2399 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2017 | 23337 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2186 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2011 | 1948 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3611 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20123 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 3584 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 9960 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 6991 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 4803 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10480 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 19907 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 35423 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 12956 | 0.010 |
Why?
|
| Pain | 1 | 2014 | 4987 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12961 | 0.010 |
Why?
|
| Massachusetts | 1 | 2011 | 8663 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 949 | 0.010 |
Why?
|
| Palliative Care | 1 | 2011 | 3490 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 9582 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 168788 | 0.000 |
Why?
|
Concepts
(229)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(102)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_